We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Stakeholders Prefer TGA’s Modified Approach to Naming Biologics
Stakeholders Prefer TGA’s Modified Approach to Naming Biologics
An Australian Therapeutic Goods Administration proposal to expand the information offered in its current naming system for biologics drew support from most respondents, with Mylan warning an alternate proposal to adopt suffixes may offer little benefit for pharmacovigilance.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor